NASDAQ OMX

XBiotech to Present Pivotal Phase 3 Data on Xilonix™ at European Society of Medical Oncology’s World Congress on Gastrointestinal Cancer

19.4.2016 14:00 | NASDAQ OMX

Del
  • First Time Pivotal Phase 3 Xilonix™ Data To Be Unveiled at Major Scientific Congress
  • Developed Specifically to Treat Advanced Cancer, Xilonix™ is First Antibody Therapy to Neutralize Biological Activity of Interleukin-1α (IL-1a)
  • Xilonix™ Recently Granted Accelerated Review for Marketing Authorization by the European Medicines Agency (EMA); a decision on Xilonix™ approval could come as early as fourth quarter 2016

AUSTIN, Texas, April 19, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next generation True Human™ antibody therapies, today announced it will present pivotal Phase 3 data for Xilonix™, the Company’s lead therapy developed for the treatment of advanced colorectal cancer, at the 18th ESMO World Congress on Gastrointestinal Cancer. This will be the first presentation of the Phase 3 data at a major scientific congress. The 18th ESMO World Congress on Gastrointestinal Cancer, considered the premier scientific event for gastrointestinal cancer, will be held June 29 to July 2 in Barcelona, Spain.

A potential breakthrough for patients with advanced colorectal cancer, Xilonix™ is specifically designed to target and neutralize interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis (the growth and spread of tumors), as well as mediate symptoms such as metabolic dysregulation (e.g., a cause of muscle loss and weight loss), fatigue and anxiety associated with advanced cancer.

The abstract, entitled “A Pivotal Phase 3 Trial of Xilonix™ in Advanced Colorectal Cancer,” will be presented by Dr. Tamas Hickish, Chair of the Xilonix™ European Phase 3 Study, and Consultant Medical Oncologist, Royal Bournemouth Hospital NHS Foundation Trust, UK. Colorectal cancer is the leading cause of malignancy in the industrialized world.

About True Human™ Therapeutic Antibodies
XBiotech is pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. Unlike previous generations of antibody therapies, XBiotech’s True Human™ antibodies are 100 percent human, derived from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

The first of these therapies, Xilonix™, for advanced colorectal cancer is in Phase 3 clinical trials in the United States with a Fast Track designation by the U.S. Food and Drug Administration (FDA). In Europe, Xilonix™ Phase 3 clinical trials have been completed, and the therapy is under accelerated review following the validation of its Market Authorization Application by the European Medicines Agency (EMA).

About XBiotech
XBiotech is a fully integrated global company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to improve the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech is expanding its state-of-the-art manufacturing with launch of a new commercial-scale facility in 2016. The manufacturing process has been designed to dramatically reduce time and cost while increasing flexibility, representing a new approach to biotech manufacturing. For more information, visitwww.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

         Contacts:
         XBiotech
         Ashley Otero
         aotero@xbiotech.com
         512.386.2930
         
         Media liaison U.S.
         Mariann Caprino
         917.242.1087
         
         Media liaison ex-U.S.
         Jonathan Kearney
         +44 20 8618 2755; Mobile: +44 7725 925 841

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

EPAM Hosts Scratch Conference in Budapest to Bring Together IT Educators Around the World23.8.2017 16:00Pressemelding

NEWTOWN, Pa., Aug. 23, 2017 (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, will host the Scratch Conference in Budapest, Hungary from August 24-25, 2017. The event is one of six conferences held globally to bring together hundreds of Scratch educators and IT experts. Developed by MIT, Scratch is a foundational tool and coding platform used primarily by children to learn the basics of programming. During this free event, attendees will hear from over 60 experts and explore all facets of computing, including best practices in using Scratch and additional tools that integrate with the platform. Several renowned speakers will attend the conference including Mitchel Resnick, Professor of Learning Research at the MIT Media Lab and Chair of the Scratch Foundation; Ariam Mogos, Learning Lead, Office of Innovation at UNICEF; and Genevieve Smith-Nunes, Entrepreneur and a Lecturer at Roeha

Novavax' Preclinical Influenza Nanoparticle Study Published in Vaccine23.8.2017 13:00Pressemelding

Novel vaccine candidate, NanoFlu(TM), outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study GAITHERSBURG, Md., Aug.  23, 2017  (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced that data from a preclinical study of its nanoparticle influenza vaccine candidate with its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) have been published in the journal Vaccine. Novavax is developing NanoFlu to protect older adults from seasonal influenza. The manuscript describes the formulation of Novavax' novel seasonal influenza vaccine candidate, NanoFlu, based on the 2017-2018 World Health Organization (WHO) recommended influenza strains. The study, conducted in ferrets, found that NanoFlu induced hemagglutination-inhibition (HAI) and microneutralizing (MN) antibodies against a broad range of influenza subtypes. In a head-to-head comparison against standard-dose and high-do

Crown Bioscience Names Dr. Leon Hall Vice President of Global Scientific Excellence23.8.2017 12:29Pressemelding

SANTA CLARA, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today the appointment of Dr. Leon Hall as Vice President of Global Scientific Excellence. In his new role, Dr. Hall will be responsible for overseeing global R&D programs and advancing Crown Bioscience's scientific excellence initiatives. "Leon's appointment reinforces Crown Bioscience's dedication to innovation and commitment to providing the highest quality therapeutic technology services," said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. "His extensive scientific and operational experience will serve Crown Bioscience well as we expand to meet the growing needs of preclinical research to the global

Blackbird Energy Inc. annonserer utnevnelsen av Allan Dixon som sjef for bedriftsutvikling23.8.2017 12:02Pressemelding

CALGARY, Alberta, 23. aug. 2017 (GLOBE NEWSWIRE) - Blackbird Energy Inc. (TSX-V:BBI) («Blackbird») har gleden av å kunngjøre utnevnelsen av Allan Dixon som sjef for bedriftsutvikling.  I denne rollen vil Dixon være ansvarlig for investorrelasjoner, kommunikasjonsinitiativer og strategiske bedriftsbevissthetsprogrammer i Nord-Amerika og Europa. Dixon har en omfattende bakgrunn i Calgarys olje- og gassindustri med erfaring fra investorrelasjoner ved Birchcliff Energy Ltd., aksjeanalyse ved National Bank Financial og investeringsrelatert bankvirksomhet ved Tristone Capital. Dixon har en bachelorgrad i handelsfag med spesialisering innen finans fra Dalhousie University. «Jeg er veldig glad for å ønske Allan velkommen til Blackbird-teamet, og jeg ser frem til å jobbe med ham. Med sin varierte bakgrunn og erfaring med å jobbe med noen av verdens fremste innovatører i bransjen, har jeg den største tillit til at han vil være et verdifullt tilskudd til teamet vårt og en ressurs fo

International Body Positive Mentor, Arabella S. Ruby, Launches New Fashion Collection Under the Xehar Brand, Arabella by Xehar23.8.2017 12:00Pressemelding

Xehar's successful ambassador marketing campaign continues to drive online sales while spreading body positive messages among millennials around the world PLAYA VISTA, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Today Xehar launches their newest collection Arabella by Xehar, an edgy and contemporary plus size fashion line targeting progressive millennials. High demand for Xehar's custom clothing lines can be seen by the recent collection Laura by Xehar, which sold out in a record 10 days. Xehar has developed a proven method in creating collections inspired by Body Positive Mentors who have a significant social media following. A photo is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/10d6e5d8-c740-4c41-aa56-2255e6f70ad9 "Customers appreciate authenticity, and we are seeing great results by sharing our products through our Body Positive Mentors," says Hadari Oshri, CEO and founder of Xehar. "We are actively searching for m

Nasdaq Offers Proprietary U.S. Equity Data Feeds from Equinix Data Center in London23.8.2017 09:11Pressemelding

NEW YORK and LONDON, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) has announced the availability of proprietary U.S. equity feeds from Equinix's London International Business Exchange(TM) (IBX®) data center - LD4 - located in Slough, U.K. As part of Nasdaq's efforts to bring U.S proprietary equities data to a larger audience, Nasdaq now offers Nasdaq TotalView and Nasdaq Basic from LD4. Nasdaq Basic combines Nasdaq Best Bid and Offer (QBBO), with either Nasdaq Last Sale (NLS), or Nasdaq Last Sale Plus (NLS Plus). "We continue to focus on working closely with our clients around the world in order to help them gain secure, efficient access to our markets," said Jeff Kimsey, Head of Global Data Products, Nasdaq. "Buy-and sell-side clients based in the U.K. can now access our U.S. data products directly from the exchange through the Equinix LD4 data center." This new Point of Presence (PoP) will allow firms direct access to U.S. mar

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom